VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions
暂无分享,去创建一个
E. Jonasch | Xian-de Liu | E. Coitiño | P. Pennisi | M. Barontini | G. Sansó | J. Bonanata | Ayelén Martín | Cecilia Mathó | Ana Vieites | M. C. Fernández | Jenner Bonanata
[1] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[2] Alexandros Kouris,et al. VarSome: the human genomic variant search engine , 2018, bioRxiv.
[3] Torsten Schwede,et al. SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..
[4] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[5] Evan Bolton,et al. Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..
[6] V. G. Antico Arciuch,et al. Role of RSUME in inflammation and cancer , 2015, FEBS letters.
[7] K. Chung,et al. E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis , 2015, BMC Cancer.
[8] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[9] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[10] Y. Xiong,et al. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. , 2015, Structure.
[11] F. Holsboer,et al. RSUME inhibits VHL and regulates its tumor suppressor function , 2014, Oncogene.
[12] G. Mills,et al. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis , 2014, Oncogene.
[13] P. Sarma,et al. Novel three missense mutations observed in Von Hippel-Lindau gene in a patient reported with renal cell carcinoma , 2013, Indian journal of human genetics.
[14] J. Prchal,et al. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. , 2013, Blood.
[15] W. Kaelin,et al. The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.
[16] Andreas Thomann,et al. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. , 2012, Chemistry & biology.
[17] Jing Hu,et al. SIFT web server: predicting effects of amino acid substitutions on proteins , 2012, Nucleic Acids Res..
[18] G. Mills,et al. Results of a high-throughput screen to identify compounds that modulate VHL proteostasis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Richard,et al. von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.
[20] Robert M. Hanson,et al. Web servers and services for electrostatics calculations with APBS and PDB2PQR , 2011, J. Comput. Chem..
[21] William Y. Kim,et al. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL , 2011, Journal of cellular and molecular medicine.
[22] Jan H. Jensen,et al. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.
[23] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[24] A. McNeill,et al. Genotype–phenotype correlations in VHL exon deletions , 2009, American journal of medical genetics. Part A.
[25] A. Schoenfeld,et al. Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes , 2009, BMC Cancer.
[26] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[27] C. Ki,et al. Improved Detection of Germline Mutations in Korean VHL Patients by Multiple Ligation-dependent Probe Amplification Analysis , 2009, Journal of Korean medical science.
[28] W. Rathmell,et al. VHL Type 2B Mutations Retain VBC Complex Form and Function , 2008, PloS one.
[29] M. Ohh,et al. NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL , 2008, EMBO reports.
[30] T. Benzing,et al. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. , 2007, Cancer research.
[31] G. Mills,et al. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners , 2006, Proceedings of the National Academy of Sciences.
[32] M. Ashcroft,et al. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. , 2006, Cancer research.
[33] V. Haase,et al. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. , 2006, Kidney international.
[34] R. Johnson,et al. pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition , 2006, Molecular and Cellular Biology.
[35] J. Frydman,et al. Folding and Quality Control of the VHL Tumor Suppressor Proceed through Distinct Chaperone Pathways , 2005, Cell.
[36] Patrick D. Sutphin,et al. Coordinate Regulation of the Oxygen-Dependent Degradation Domains of Hypoxia-Inducible Factor 1α , 2005, Molecular and Cellular Biology.
[37] R. Osman,et al. Inactivation of VHL by Tumorigenic Mutations That Disrupt Dynamic Coupling of the pVHL·Hypoxia-inducible Transcription Factor-1α Complex* , 2005, Journal of Biological Chemistry.
[38] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] W. Rathmell,et al. In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations , 2004, Cancer Research.
[40] M. Barontini,et al. Familial isolated pheochromocytoma presenting a new mutation in the von Hippel-Lindau gene. , 2004, American journal of hypertension.
[41] J. Klco,et al. pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development , 2004, Molecular and Cellular Biology.
[42] J. Åqvist,et al. Molecular Dynamics Simulations of Water and Biomolecules with a Monte Carlo Constant Pressure Algorithm , 2004 .
[43] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[44] J. Frydman,et al. The Hsp70 and TRiC/CCT Chaperone Systems Cooperate In Vivo To Assemble the Von Hippel-Lindau Tumor Suppressor Complex , 2003, Molecular and Cellular Biology.
[45] V. Barr,et al. Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype. , 2002, Cancer research.
[46] Yigong Shi. Faculty Opinions recommendation of Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. , 2002 .
[47] M. Seyfarth,et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. , 2002, Blood.
[48] W. Kaelin,et al. Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity , 2002, Molecular and Cellular Biology.
[49] Nathan A. Baker,et al. Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[50] M. Ivan,et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.
[51] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[52] R. Burk,et al. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] R Stearman,et al. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[55] W. Kaelin,et al. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.
[56] R. Klausner,et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Webster,et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.
[58] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[59] Fan,et al. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. , 1995, Cancer research.
[60] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[61] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[62] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[63] P. Jemth,et al. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. , 2006, Oncogene.
[64] W. Krek,et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL , 2003, Nature Cell Biology.
[65] David I Stuart,et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. , 2002, Nature.
[66] A. Sakurai,et al. [von Hippel-Lindau syndrome]. , 2001, Ryoikibetsu shokogun shirizu.
[67] W. Linehan,et al. Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.
[68] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[69] C. Brooks. Computer simulation of liquids , 1989 .